Helping People Adhere to Treatment Helps Treatment Succeed

The development of direct-acting antiviral (DAA) treatments has revolutionised the treatment of hepatitis C in Australia. DAAs are effective and, when patients follow the medication regime, can cure more than 90% of those who take the treatment. But at the moment there are limited resources to inform and guide health professionals as they try to provide adherence support to those undergoing DAA treatment.

Medication adherence refers to the way an individual takes a medication, including the use of the correct medication, the correct dose and time, duration and timely refilling of repeat prescriptions.

Continue reading “Helping People Adhere to Treatment Helps Treatment Succeed”

Will South Australians Miss Out on Future Cures?

It is a rare thing that a cure can be found for a chronic disease.

Yet such a thing did happen recently with the revolution in treatments for hepatitis C. The new Direct-Acting Antiviral medicines could cure over 90 per cent of those treated, in 8 to 24 weeks with minimal side effects. Compare this to previous treatment regimens of 24 to 48 weeks, often with severe side effects, and cure rates of only 50 to 80 per cent.

Such breakthroughs would not have been possible without concerted, meticulous research and coordinated clinical trials around the world. So it is disappointing to hear (see media report and  AMA article) that South Australia’s brand new state-of-the-art Royal Adelaide Hospital, will have no room for clinical trials.

It is believed that at best, only 15 per cent of the 350 current trials currently underway will be accommodated at the new RAH.

Leading medical experts and community organisations have voiced their concern over this lack of provision.

Continue reading “Will South Australians Miss Out on Future Cures?”